WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2013 Annual General Meeting

Nov 07, 2013, 06:44 ET from WuXi PharmaTech (Cayman) Inc.

SHANGHAI, Nov. 7, 2013 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced shareholder resolutions adopted at its annual general meeting of shareholders held in Hong Kong on November 7, 2013.

At the meeting, WuXi PharmaTech shareholders approved the re-election of incumbent Class C directors Dr. Ge Li and Stewart Hen, each to serve a three-year term.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

For more information, please contact:

Ronald Aldridge Director of Investor Relations +1-201-585-2048 ron_aldridge@wuxiapptec.com

Aaron Shi Associate Director of Corporate Communications +86-21-5046-4362 aaron_shi@wuxiapptec.com

SOURCE WuXi PharmaTech (Cayman) Inc.